What does Merida Biosciences do?
Merida Biosciences is a biotechnology company based in Cambridge, MA that is developing a new class of precision therapeutics. Its novel platform is designed to target pathogenic antibodies, which are at the core of a range of autoimmune and allergic diseases.
How much did they raise?
The company raised $121M in Series A funding. The round was led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures, with participation from GV and Perceptive Xontogeny Venture Funds. This infusion marks a significant step in bridging early-stage innovation with growth potential.
What are their plans for the money?
The funds will be used to expand operations and ramp up research and development efforts. This investment is expected to accelerate the development of antibody-like therapeutics that offer targeted depletion of pathogenic antibodies, potentially reducing the side effects associated with current treatments.
What have they achieved so far?
Merida Biosciences has already made notable strides with its innovative therapeutic platform, targeting conditions such as Graves’ disease, allergy, and primary membranous nephropathy. Its leadership team, with deep experience in the biopharmaceutical industry, has helped secure early success and set a robust foundation for future growth.
